Managing Ocular Pain and Inflammation After Cataract Surgery: Differentiating Among the Nonsteroidal Antiinflammatory Drugs Part 2

Eric Donnenfeld, MD, moderator
Cynthia Matossian, MD
Sheri Rowen, MD
Inder Paul Singh, MD
CONTENT SOURCE
This continuing medical education (CME) activity captures content from an event held in February of 2017 at the ACES/SEE meeting.

TARGET AUDIENCE
This certified CME activity is designed for ophthalmologists involved in the comanagement of postoperative cataract patient management.

LEARNING OBJECTIVES
Upon completion of this activity, the participant should be able to:

• Describe the pharmacokinetic properties of the bromfenac molecule
• Assess the ability of topical ophthalmic NSAIDs to treat postoperative inflammation and pain in a cataract patient
• Analyze the safety profile of the bromfenac molecule
• Discuss the obstacles patients face in compliance and adherence
• Develop a plan to communicate compliance obstacles with patients

ACCREDITATION STATEMENT
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TO OBTAIN AMA PRA CATEGORY 1 CREDIT™
To obtain AMA PRA Category 1 Credit™ for this activity, you must read the activity in its entirety and complete the Post Test/Activity Evaluation Form, which consists of a series of multiple choice questions. To answer these questions online and receive real-time results, please visit evolvemeded.com and click “Online Courses.” Upon completing the activity and achieving a passing score of over 70% on the self-assessment test, you may print out a CME credit letter awarding 1 AMA PRA Category 1 Credit.” Alternatively, please complete the Post Test/Activity Evaluation Form and mail or fax to Evolve Medical Education LLC, PO Box 358, Pine Brook, NJ 07058; Fax: (610) 771-4443. The estimated time to complete this activity is 1 hour.

DISCLOSURE POLICY STATEMENT
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty members have the following financial relationships with commercial interests:

Eric Donnenfeld, MD, moderator
Ophthalmic Consultants of Long Island
Long Island, New York

Cynthia Matossian, MD
Matossian Eye Associates
Pennsylvania and New Jersey

Sheri Rowen, MD
NVision Centers
Newport Beach, California

Inder Paul Singh, MD
The Eye Centers of Racine and Kenosha
Racine, Wisconsin

FACULTY CREDENTIALS

Eric Donnenfeld, MD, moderator
Ophthalmic Consultants of Long Island
Long Island, New York

Cynthia Matossian, MD
Matossian Eye Associates
Pennsylvania and New Jersey

Sheri Rowen, MD
NVision Centers
Newport Beach, California

Inder Paul Singh, MD
The Eye Centers of Racine and Kenosha
Racine, Wisconsin
Imprimis Pharmaceuticals; Shire Plc; and TearScience. Stock/Shareholder: Checked-Up; Imprimis Pharmaceuticals; Ocular Therapeutics; PRN-Physician Recommended Nutraceuticals; RPS; Strathspey Crown LLC; and TearLab Corporation.

Sheri Rowen, MD, has had a financial agreement or affiliation during the past year with the following commercial interest(s) in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Bausch + Lomb; Johnson & Johnson Vision; Omeros Corporation; Shire Plc; and TearLab Corporation.

Inder Paul Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interest(s) in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Bausch + Lomb; Glaukos Corporation; Imprimis Pharmaceuticals; Ivantis; Johnson & Johnson Vision; Shire Plc; and Sun Pharmaceutical Ltd.

EDITORIAL SUPPORT DISCLOSURES
Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; and Michelle Dalton, medical writer; have no real or apparent conflicts of interest to report.
Rishi Singh, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech; and Regeneron Pharmaceuticals.

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, Advanced Ocular Care, Cataract & Refractive Surgery Today, or Sun Pharmaceutical Industries Ltd.

Go to evolvemeded.com/online-courses/ to view the online version of this supplement.

Go to evolvemeded.com/online-courses/ to view the online version of this supplement.
Managing Ocular Pain and Inflammation After Cataract Surgery: Differentiating Among the Nonsteroidal Antiinflammatory Drugs, Part 2

Phacoemulsification with intraocular lens implantation has become the gold standard surgical procedure for cataract removal. Although there is potential for postoperative pain and inflammation, the benefits patients receive from the cataract surgery far outweigh these potential complications. Risk factors for inflammatory complications may include those patients with anterior segment pathology, uveitis-related damage to the blood-aqueous barrier, diabetes, glaucoma, or those eyes previously exposed to surgery.

Nonsteroidal antiinflammatory drugs (NSAIDs) can reduce postoperative pain and can reduce the risk of postoperative inflammation, thereby improving patient comfort. The incidence of postoperative pain is estimated at about one-third during the early postoperative period, but almost 80% of those patients continue to experience pain even after they have left the surgical facility. Postoperative inflammation—typically assessed as anterior chamber cell counts and flare—is also fairly common during the early-to-intermediate postoperative period. This, too, has been regarded as an acceptable risk profile given the benefits derived from cataract surgery.

Bromfenac 0.075% (BromSite) is the latest entry in the NSAID market. Evolve gathered some leading cataract surgeons to discuss how this new NSAID differs from others, and its advantages.

—Eric Donnenfeld, MD, moderator

Eric Donnenfeld, MD: Most of us use nonsteroidal antiinflammatory drugs (NSAIDs) in our practices. How important are they, and what role do—or should—NSAIDs play in cataract surgery?

Sheri Rowen, MD: I have used NSAIDs since I began cataract practice. In an early retrospective study I performed, I found the rates of cystoid macular edema (CME) were much lower with NSAID use than after corticosteroid use alone, even with the earlier generation NSAIDs. I have been using NSAIDs ever since. When we consider pain control, pupil management, inflammation, and CME (even though that has not been studied as extensively), we know NSAIDs provide a great benefit. For my patients who do develop CME, I have found NSAIDs can quickly resolve it. For all those reasons, I believe the use of NSAIDs is critical in my cataract practice.

Cynthia Matossian, MD: Studies have shown that starting NSAIDs prior to surgery, even by a day, will make a difference in maintaining mydriasis at the time of cataract surgery. I tell my patients to start the NSAIDs 3 days before surgery, but I suspect many do not begin really using them until the day before surgery.

Dr. Donnenfeld: Dr. Singh, you see a lot of high-risk patients in your practice. How long do you continue your NSAIDs following cataract surgery? Should certain patients be prescribed NSAIDs for a longer course?

Inder Paul Singh, MD: That is an interesting debate. We evaluated our patients internally and looked at the optical coherence tomography images. We never published our data, but we compared outcomes after keeping patients on NSAIDs for 1 month postoperatively or 3 months postoperatively. We found a difference in the overall macular thickness—it was slightly thinner in the group on postoperative NSAIDs for 3 months. Based on our internal results, when patients have any kind of diabetic disease (controlled or not), any kind of epiretinal membrane or other macular pathology, or if I think patients are prone to fibrosis (especially for those who have opted for premium lenses), I now keep them on NSAIDs for 6 to 8 weeks, if not longer. But on average, after uncomplicated cases, I like keeping patients on postoperative NSAIDs for 6 weeks.

Dr. Donnenfeld: We published a paper on the pharmacokinetic dose response to NSAIDs, and found that initiating NSAIDs 1 to 3 days before surgery results in significantly more pupil dilation, less inflammation, more rapid healing, and less risk of macular thickening on OCT compared to starting at 1 hour or not using an NSAID. Based on that, I think 2 days preoperatively is the optimal time to start NSAIDs.

Numerous studies on the use of NSAIDs show they improve pupillary dilation, improve pain control, and improve short-term inflammation and short-term visual acuity (VA). There has been some controversy on the longer-term effects on VA, however. Others have questioned whether the body of evidence in the literature is convincing enough to warrant routine NSAID use.

Dr. Singh: We have been involved with steroid trials for use after cataract surgery. When you are involved in these studies, you are not allowed to use NSAIDs as part of the postoperative care. We have found an amazing difference in the two sets of eyes—when you do not use an NSAID during either the preoperative or postoperative periods, the eyes are not as “happy,” not as quiet. They are more likely to have hyperemia, the conjunctiva is often more edematous, and patients are more likely to complain about their postoperative course.
I was involved in the Dextenza study—this is a dexamethasone steroid implant that fits into the inferior punctum. When we placed it right after surgery, we found it helped reduce the need for steroid drops.\(^{37}\)

When I first came out of fellowship, steroids were the standard of care. But then the data started being published on the outcomes after using NSAIDs, and I thought, ‘How can I not use an NSAID in my postoperative cataract patients?’ The results were just too positive. It definitely helped me grow my practice.

**POSTOPERATIVE PAIN**

**Dr. Donnenfeld:** Let us discuss pain for a moment—for some patients, postoperative pain after cataract surgery may not be debilitating, but, for others with lower pain thresholds, it may be excruciating. It is probably safe to say that the less postoperative pain a patient endures, the more favorable the overall experience is likely to be. Do you think we talk about postoperative pain enough?

**Dr. Matossian:** There are two things by which patients judge their surgeon after undergoing cataract surgery. In the immediate postoperative period, it is how well they see compared to their preoperative vision. Later, it is whether or not they experienced pain or discomfort during the procedure or during the immediate postoperative period. If we are able to provide our patients with better visual outcomes and reduce the amount of postoperative inflammation, reduce their light sensitivity in the immediate postoperative period, and reduce the amount of pain and discomfort they are likely to experience, they are going to be more positive about their experience, and they are going to view their surgery as more successful.

**Dr. Rowen:** When we create a wound (whether it is for cataract surgery or a refractive procedure), in my experience, patients respond better when they have NSAIDs for pain control. Our incisions might be smaller than other types of surgeries, but we are still disrupting the epithelium. We are still creating a release of prosta-glandins. Discomfort is a reality—patients do not tend to discuss this much. They expect pain, but the difference in what we see without postoperative NSAID use and with it is definitely noticeable. I think Dr. Matossian is correct when she notes that patients who have seamless surgery and do not really feel the postoperative effects as much are much happier. That is what we should address.

**Dr. Singh:** I always ask colleagues, what is your goal of cataract surgery? Is the goal spectacle independence after surgery? Or is it to have a happy patient? They do not have to be mutually exclusive, either. Everyone here has mimicked what we see in our practice as well. It is the overall experience—from preoperative, to intraoperative, to postoperative—that patients remember. We asked patients in our practice when they start discussing their surgery—how long before they start talking to their friends about their outcomes? In our patient population, it was within that first week. At postoperative day 1, they realize there is a difference, but they do not start talking to people about their experience for another few days. And their friends want to know—friends will ask about eye irritation or light sensitivity, and they want to know about the pain.

Everyone has some level of postoperative inflammation in the immediate postoperative period, but pain can be as simple as a patient noting their eye is a little sore when they wake up. It does not have to be patients complaining about throbbing or opening their eyelids hurt. The definition of pain is going to vary. In cataract surgery, our threshold for comfort has gone down so much; patients expect to have a beautiful, easy course. We have found that to be particularly true with our premium IOL patients.

**Dr. Rowen:** Bromfenac 0.075% (BromSite) is approved as a twice-daily medication.\(^{48}\) When we start to think about pain control, I use bromfenac 0.075% (BromSite) twice daily for the first week, and then taper to once daily after that. In our experience, it is that first week where the patient is most likely to feel pain. By dosing twice daily, you are giving the patient just a little bit longer control of pain/discomfort/irritation.

**Dr. Donnenfeld:** That is exactly what patients are looking for—they want quality vision and a quality experience, and they are both equally important. During their postoperative day 1 visit, they are already telling their friends about their experience. If the experience was not what they expected it to be, no matter how good the visual outcomes are from your perspective as a surgeon, the patient does not care. They care about their perception of how the operation went.

I discuss pain and that it is the enemy of surgery with my patients during our consult. When patients are uncomfortable, they tend to flinch or move their eyes or turn their heads, and it makes surgery much more dangerous. When we are in the operating room and patients are obviously in discomfort or they complain, we have increased the anesthesia. Sometimes that works, but sometimes it confuses the patients and may create some untoward movement as well. In my mind, controlling pain is not just a cosmetic discussion. It is a therapeutic discussion to have with the patient, because it will inevitably enable you to perform a safer surgery. It is another reason I believe in using NSAIDs and consider them invaluable in improving outcomes.
DIFFERENTIATING NSAIDS

Dr. Donnenfeld: In your opinions, how should surgeons differentiate the available NSAIDs for use in cataract surgery? For me, there are three parameters that I consider when I am evaluating an NSAID. First, I evaluate the molecule. Then, I evaluate the concentration of that molecule. Lastly, I consider the vehicle in which the molecule is delivered. All three components are equally important to me. What are your priorities? How do you decide which NSAID to use?

Dr. Matossian: The bromfenac molecule has been available for a long, long time, both here in the United States and in other nations. We know its safety profile. We know its efficacy. It is delivered in the DuraSite vehicle, which is an extended-release type of artificial tear that has various ingredients in it that make the eye feel comfortable and has been shown in studies to be safe and nontoxic.

With the newest version of bromfenac (0.075%, BromSite) in DuraSite, I have been asked whether the twice-daily dosing will increase the amount of active ingredient on the surface of the eye. And will that, in turn, lead to negative problems?

Simply put, no. Bromfenac 0.075% (BromSite) is suspended within the DuraSite vehicle. With sheer blinking the active ingredient is released, and it penetrates immediately into the cornea and into the anterior chamber. The active ingredient is not just ‘spending time’ on the surface of the eye.

Dr. Rowen: Bromfenac has one of the most potent penetration profiles of any molecule on the market. The cLogP of this molecule shows it can penetrate the cornea almost instantaneously. As Dr. Matossian said, it is released with a blink, it penetrates the cornea, and because it is an extremely potent COX-1 and COX-2 blocker, there is an almost immediate response.

Dr. Singh: It is a well-known point that less than 5% of a drug is actually absorbed in the eye when you instill a drop. There are multiple factors that account for that—blinking, nasolacrimal evacuation, tear turnover, etc. So when we evaluate how a drug can be delivered more effectively or absorbed more effectively, the options are to change how long it can be absorbed or change the vehicle. Due to its lipophilic properties, bromfenac 0.075% (BromSite) does not need to be hydrolyzed by corneal esterases; therefore, it can be absorbed fairly rapidly. Also, with the DuraSite vehicle increasing residence time, the bromfenac molecule has more potential opportunities for absorption. It is important to note that DuraSite does not increase corneal toxicity due to the ability of the vehicle to sequester the nonabsorbed molecule within its matrix and prevent it from residing directly on the epithelium. When comparing absorption data, bromfenac 0.075% (BromSite) with DuraSite demonstrated higher concentrations in the aqueous compared to a bromfenac 0.09% (Bromday) without DuraSite, suggesting the vehicle allows for greater absorption at a lower concentration.

Dr. Donnenfeld: There are several NSAIDs approved for use in ophthalmic surgery: bromfenac, diclofenac, ketorolac, nepafenac, and suprofen. We tend to use ketorolac, nepafenac, and bromfenac after cataract surgery. All three are potent NSAIDs, but as Dr. Singh pointed out, bromfenac is the most potent so its concentration is lower than the others.

Ketorolac was really the first NSAID we used routinely, but it is not as potent, and it is much more toxic to the cornea. As currently available, ketorolac 0.5% is a very toxic molecule—during the registration trials, up to 40% of subjects had significant burning and stinging associated with ketorolac. That is about what you are going to see if you use a generic NSAID. Ketorolac was also highly associated with epitheliopathy, corneal melts, and decreased visual acuity. I strongly counsel against using this molecule, especially in people with ocular surface disease.

Dr. Singh: In our patient population after an internal review of our diagnosis codes looking for patients with a diagnosis of dry eye-related diseases, we found almost 80% of our patients may have some type of ocular surface disease. As glaucoma specialists, we tend to see a higher population of patients with surface issues due to glaucoma medications and systemic comorbidities.

Dr. Rowen: There is nothing worse than doing a perfect surgery and 3 weeks later the patient comes in with his or her corneal epithelium completely disrupted from the ketorolac.

Dr. Donnenfeld: We heard from this panel and know from the literature that bromfenac is safe and exceptionally well tolerated. The DuraSite vehicle is a mucoadhesive molecule that adheres to the surface and is an extraordinarily potent ocular surface protectant.

Dr. Singh: Other NSAIDs use vehicles that make the residence time on the cornea longer, but may also cause more tolerability issues. When I have used eye drops with some of these polymers, like guar gum or hyaluronic acid, I hear more complaints from patients than when I have used other NSAIDs.
Dr. Matossian: Plus, as Dr. Rowen noted, some patients note a little bit of a foreign body sensation during the immediate postoperative period, especially at the site of the incision. In my experience, adding the mucoadhesive vehicle that is used in DuraSite really soothes the eye with each blink.

Dr. Donnenfeld: And the mucoadhesive stays on the ocular surface a longer period of time. We know that the turnover time with the tear film is just minutes.\textsuperscript{51-54} There is evidence that DuraSite helps lengthen the time a solution stays on the surface.\textsuperscript{52,56} Other medications use DuraSite as well, including azithromycin and besifloxacin.\textsuperscript{57,58} Tear film studies have shown that antibiotics can remain for 3 to 5 days.\textsuperscript{59,60} Those levels cannot be achieved without the use of a vehicle. Let me ask, in your opinion, what is the effect of having DuraSite vehicle on the penetration rates of the active ingredient (drug) into the eye?

Dr. Singh: As Dr. Matossian pointed out earlier, that vehicle helps keep the drug on the surface longer, but it also keeps it in a “protective pocket” of sorts in the DuraSite vehicle itself. With any vehicle, our concerns should be that something is kept on the surface for any length of time can cause epitheliopathy over the long term. But that is not the case here—the active ingredient is protected within a small pocket of the DuraSite molecule. When the DuraSite reacts with the tear film, an ionization occurs to release the drug. Bromfenac is highly lipophilic, so it will absorb quickly. It does not have a lot of time to contact the epithelium. Every blink replenishes the surface and releases the drug, it goes back into the conjunctival cul-de-sac, the patient blinks again, and the whole process is repeated resulting in a chronic, slow release throughout the day. For me, that is an important point. We are not getting this big bolus of medicine in the morning and then nothing throughout the day. This particular vehicle ensures there is a slow release throughout the waking hours. I think that is a main reason this drug helps control pain and discomfort a little bit more continuously than having a bolus in the morning.

Dr. Rowen: In addition, it was shown that aqueous humor concentrations of bromfenac did increase over a generic formulation using the DuraSite vehicle on the ocular surface. It goes to the point that one drop continues to enter through the cornea to the anterior chamber, and you get that aqueous concentration exactly where you need it. You have the DuraSite residence time coating the cornea, you have the bromfenac going into the eye to the target tissue where the COX-1 and COX-2 enzymes reside and are released. Having twice as much active ingredient could be a bonus in controlling inflammation.

Dr. Donnenfeld: Getting twice as much nonsteroidal to the eye is obviously an advantage, but what is the effect of having both DuraSite and bromfenac on the ocular surface? What does that do for ocular surface pain after surgery? Does it have a significant effect on controlling pain because you have increased contact time?

Dr. Matossian: Yes—having the DuraSite on the surface definitely decreases the pain, and that is our goal for our patients—to minimize pain and discomfort.

Dr. Rowen: The interesting part of what you raised is: would the DuraSite be comparable to the bromfenac 0.075% (BromSite) in terms of the foreign body irritation on the surface? We do not think we actually know that directly. That would be something worthy of future investigation.

Dr. Donnenfeld: How important do you think preventing pain is as an indication?

Dr. Singh: To me, that is an extremely important issue for a number of reasons. We try to educate our patients about the medications we prescribe, about the brand-name medications. They want to know how long they have to take the medication and why. Up until this indication on this NSAID, though, I could not tell them anything I prescribed would prevent pain. Now I have a way to put a better value on their purchase, so to speak: “Is this prevention of pain worth it to me?” Giving our patients enough value for that purchase is important.

Patients are most fearful of losing vision or going blind after cataract surgery, but their second biggest fear is always pain. Even though most of our patients do not have high pain levels postoperatively, I think it is a big benefit for patients to know that they can take something to alleviate and prevent the pain. It is also why I tell my patients I am prescribing a name brand and not a generic alternative, even though generics are available.

Dr. Matossian: I think that is really key. Patients are worried about going blind and the pain of surgery. If we can get them engaged in the process, in the decision-making process of purchasing a branded product whose indication is prevention of inflammation and prevention of pain—that is great.

The bottle size is also very important. That is another key feature.

Dr. Singh: Why do you consider bottle size a key feature?

Dr. Matossian: Because one of the things that our patients complain about most is how little medicine they get and that it does not last long enough. This is especially true for our cataract-age, elderly patients. They have a harder time getting the drops into their eye, and they tell us they often miss, so they end up using more drops than they anticipated. Or their hands shake. They are frustrated that, yet again, they have to go to the pharmacy, and purchase another bottle, and then we get the call backs.

So, my technicians are tied up trying to get another bottle certified or preapproved for that patient, because they have gone through it too quickly. And then the patient gets upset at us. That negativity and anger is directed at the practice and at the surgeon when we have nothing to do with it. I would rather not have that
dialogue at all, and instead find an alternative. A bigger 5-ml bottle is welcomed. Hopefully, it is a big enough bottle. It has about 100 drops in it to get the patient through both eyes and the second sequential cataract surgery.

ON- AND OFF-LABEL USES

Dr. Donnenfeld: What are the FDA indications? How do you actually prescribe it clinically yourselves?

Dr. Rowen: Well, the FDA indication is at twice a day for 14 days. I think most of us prescribe NSAIDs for a longer period postoperatively, especially if there are complications or if the patient is at a higher risk. We want to control the blood-aqueous barrier after cataract surgery. I have been telling patients to use this for 2 days prior to surgery, and once or twice daily for the first week, followed by once daily for the next 4 to 5 weeks.

Dr. Donnenfeld: Does anyone have any different uses of the medication?

Dr. Matossian: I prescribe it once a day because I know how potent bromfenac is, and we have used that molecule in the past. But I do tell patients to use it for 8 weeks to ensure we are past the 6-week point where we might see some CME.

Dr. Singh: I am kind of a hybrid. I prescribe it twice a day, but after the first week, I drop it to once daily. But I also recommend patients dose twice a day for 3 days before surgery.

Dr. Matossian: That is what I prefer, too.

Dr. Rowen: I recommend predosing for 2 days before surgery.

Dr. Matossian: I do 3 days before, twice a day. Then once a day thereafter.

Dr. Singh: There are a lot of us who have incorporated using a femtosecond laser in our cataract surgeries to make the arcuate incisions. There are studies that now show an increased risk of prostaglandin release after the femtosecond portion when compared to standard cases. Clinically, I have found NSAIDs do help prevent miosis from occurring. But for pain, in general whenever we are doing any kind of surface or conjunctival work, or when we need to use a peripheral iridotomy, recommending patients predose is a good idea. I am especially cognizant of that with my femtosecond laser cataract patients. It is really important to have that twice-a-day dosing beforehand.

Postoperatively, I tend to recommend only once a day because the data show we are getting twice as much of the bromfenac molecule in the anterior chamber. The bromfenac 0.09% (Bromday) studies compared once daily in each arm, with predosing. So I am comfortable with dosing before twice daily, but then only once a day after surgery.

Our higher risk patients need more predosing and postoperative dosing. I also increase the pre- and postdosing for any patient who has a history of macular or inflammatory issues.

—Cynthia Matossian, MD
I will say, anecdotally, however, that I notice a difference, particularly with my femtosecond laser-assisted patients. When we see them on postoperative day 1, the conjunctiva can sometimes look a little boggier from the suction clip. But after using bromfenac 0.075% (BromSite), it was nice to see the conjunctiva—more than the anterior chamber—looked rather quiet. It was not that the anterior chamber was much quieter or that the complaints of pain were much less, but it really struck me how quiet the conjunctiva looked, how relaxed it seemed. With all the options we have, it is not that one is good and another is not, but there are some nuanced differences among our choices that may lead us to choose one NSAID over another.

**Dr. Donnenfeld:** Any other case examples?

**Dr. Matossian:** This is not a specific patient, but, overall, my patients comment on how good their eye feels after surgery, where I have not had that comment from a previous branded NSAID. They definitely talk about the gel, the mucoadhesive characteristics of the drop. They specifically say the drug feels good, which I have never heard about any other medication.

**Dr. Rowen:** Soothing is the word my patients use most often.

**Dr. Matossian:** I have also found it useful (off-label) for my dry eye patients. I use it mostly after intense pulsed laser, where these patients already have a pre-existing ocular surface disease and a fairly compromised corneal surface. They are already uncomfortable. After an intense pulsed laser, I am manually expressing their meibomian glands, and I am causing some kind of mechanical pressure on those glands. That can lead to increased irritation for patients, and I have found bromfenac 0.075% (BromSite) really eases that discomfort. I recommend it twice daily for 7 days after the intense pulsed laser procedure.

**Dr. Singh:** Any time we are manipulating the ocular surface, I think there is great potential to use an NSAID. Off-label uses outside of cataract surgery make sense to me—I also use it when there are sutures on the conjunctiva.

**Dr. Donnenfeld:** In closing, I think we can all agree that NSAIDs play an extraordinarily significant role in the management of inflammation and the prevention of pain following cataract surgery. Bromfenac 0.075% (BromSite) is a very welcome addition to the NSAID market. And we find that, because the DuraSite vehicle increases contact time on the ocular surface, there are higher aqueous humor concentrations. And we look forward to more clinical evidence about the efficacy of this medication and (perhaps) its efficacy in areas other than postoperative cataract surgery.
Differentiating Among the Nonsteroidal Antiinflammatory Drugs


20. Hossain KS, Hatcher J, Bowman LM. Aqueous humor concentration of Bromfenac 0.09% (Bromday) compared with Bromfenac Refresh Endura 0.017% (Bromstat) in cataract patients undergoing phacoemulsiﬁcation after 3 days dosing. Presented at: Association for Research in Vision and Ophthalmology; May 9-13, 2013. Seattle, Washington.


1. Nonsteroidal antiinflammatory drugs (NSAIDs) have been used after cataract surgery for what purpose? (Choose all that apply)
   a. Prevention of pain
   b. Prevention of cystoid macular edema
   c. Improve visual acuity
   d. IOP control
   e. Avoid corticosteroid use

2. Initiating NSAID use ___ day(s) before surgery has been shown to result in a decreased risk of macular thickening on optical coherence tomography.
   a. 0
   b. 0-2
   c. 1-3
   d. 3-5

3. According to the panel, using only a steroid and not a concurrent NSAID(s) during the postoperative period can lead to ___________
   a. increased hyperemia
   b. reduced edema
   c. reduced amount of time for wound healing
   d. increased IOP spikes

4. The panel recommends using which parameters to differentiate among the various NSAIDs? (Choose all that apply)
   a. Molecule safety
   b. Molecule concentration
   c. Vehicle used to deliver molecule
   d. Time on market
   e. Molecule pharmacokinetic data

5. In general, what percentage of a drug is absorbed in the eye after a topical drop is instilled?
   a. 1%
   b. 3%
   c. 5%
   d. 7%

6. Studies on NSAIDs have shown which is most toxic to the cornea?
   a. Bromfenac
   b. Diclofenac
   c. Ketorolac
   d. Nepafenac

7. The use of femtosecond lasers in cataract surgery has increased, and with it an increased risk of prostaglandin release after the femtosecond laser portion of the surgery. Incorporating the use of NSAIDs during the preoperative period __________
   a. Is not necessary when using femtosecond lasers
   b. Should be done 3 to 4 days earlier than for patients undergoing standard phaco
   c. Should be limited to the “day of” surgery only
   d. Can help prevent miosis

8. An 82-year-old patient with well-controlled diabetes presents for cataract surgery. An ocular examination does not find any evidence of diabetic macular edema or diabetic retinopathy. How long would the panelists recommend you keep this patient on NSAIDs after surgery?
   a. No difference in postoperative course from nondiabetic patients
   b. 6 to 8 weeks after surgery, with a preplanned taper to coincide with corticosteroid use
   c. 4 weeks after surgery, with corticosteroid use planned for an additional month
   d. 3 months after surgery

MANAGING OCULAR PAIN AND INFLAMMATION AFTER CATARACT SURGERY:
DIFFERENTIATING AMONG THE NONSTERoidal ANTIINFLAMMATORY DRUGS PART 2
**Did the program meet the following educational objectives?**

<table>
<thead>
<tr>
<th>Objective</th>
<th>Agree</th>
<th>Neutral</th>
<th>Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Describe the pharmacokinetic properties of the bromfenac molecule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assess the ability of topical ophthalmic NSAIDs to treat postoperative inflammation and pain in a cataract patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analyze the safety profile of the bromfenac molecule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discuss the obstacles patients face in compliance and adherence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Develop a plan to communicate compliance obstacles with patients</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Your responses to the questions below will help us evaluate this CME activity. They will provide us with evidence that improvements were made in patient care as a result of this activity as required by the Accreditation Council for Continuing Medical Education (ACCME).**

Name and email: ______________________________________________________________________________________

Do you feel the program was educationally sound and commercially balanced? □ Yes □ No

Comments regarding commercial bias: ______________________________________________________________________________________

Rate your knowledge/skill level prior to participating in this course: 5 = High, 1 = Low __________________________

Rate your knowledge/skill level after participating in this course: 5 = High, 1 = Low __________________________

Would you recommend this program to a colleague? □ Yes □ No

Do you feel the information presented will change your patient care? □ Yes □ No

Please identify how you will improve/change: ______________________________________________________________________________________

Change the management and/or treatment of patients. Please specify: ______________________________________________________________________________________

Create/revise protocols, policies, and/or procedures. Please specify: ______________________________________________________________________________________

Please identify the barriers to change.

□ Cost □ Lack of consensus or professional guidelines □ Lack of administrative support □ Lack of experience

□ Lack of time to assess/counsel patients □ Lack of opportunity (patients) □ Reimbursement/insurance issues

□ Lack of resources (equipment) □ Patient compliance issues □ No barriers □ Other

Please specify: ______________________________________________________________________________________

To help evaluate this CME activity, may we contact you by email in 1 to 2 months to see if you have made this change? If so, please provide your email address below.

____________________________________________________________________________________________

____________________________________________________________________________________________

Please list any additional topics you would like to have covered in future Evolve Medical Education LLC CME activities or other suggestions or comments.

____________________________________________________________________________________________